# Pharmacokinetics of HLD200 in Children and Adolescents With ADHD

> **NCT01907360** · PHASE1,PHASE2 · COMPLETED · sponsor: **Ironshore Pharmaceuticals and Development, Inc** · enrollment: 29 (actual)

## Conditions studied

- Attention-Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** HLD200 (methylphenidate hydrochloride)

## Key facts

- **NCT ID:** NCT01907360
- **Lead sponsor:** Ironshore Pharmaceuticals and Development, Inc
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2021-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01907360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01907360, "Pharmacokinetics of HLD200 in Children and Adolescents With ADHD". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01907360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*